Explaining Brazil #110: Bolsonaro’s “miracle” cure for Covid-19

The world has abandoned chloroquine as a possible cure against the coronavirus. But Brazil's Bolsonaro is doubling down on his bet

The World Health Organization announced it is suspending all trials on chloroquine after a recent study published by medical journal Lancet buried any hope chloroquine could lead to the end of the pandemic. But that hasn’t dissuaded President Jair Bolsonaro one tiny bit, and Brazil will continue using the antimalarial medicine in tests.

Meanwhile, Brazil is widely regarded as the world’s new Covid-19 epicenter — already registering more new daily deaths than any other country, despite its limited testing capacity.

Support this podcast →Support this podcast →

Listen and subscribe to our podcast from your mobile device:

Spotify | Apple Podcasts | YouTube | Google Podcasts | Deezer

On this episode:

  • Rosana Richtmann is an infectious disease specialist at the Emilio Ribas Institute, in São Paulo — an institution that is now working exclusively with Covid-19 patients. Dr. Richtmann holds a Ph.D. in Epidemiology from the University of Freiburg, in Germany. She is also a member of the Brazilian Infectiology Society and has been a leading voice against misinformation about contagious diseases and vaccination.

Background reading:

Explaining Brazil is made by:

  • Gustavo Ribeiro, editor in chief of The Brazilian Report. He has extensive experience covering Brazilian politics. His work has been featured across Brazilian and French media outlets, including Veja, Época, Folha de S.Paulo, Médiapart, and Radio France Internationale.
  • Euan Marshall, editing. Euan is a journalist and translator who has lived in São Paulo, Brazil since 2011. Specializing in Brazilian soccer, politics and the connection between the two, his work has been published in The Telegraph, Al Jazeera, The Independent, among others.

Do you have a suggestion for our next Explaining Brazil podcast? Drop us a line at [email protected]

Don’t forget to follow us on Twitter and Facebook.